Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 3/20 | 0.75 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.75 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.75 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.59 |
| ▸ | AHCY | P23526 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387721 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| Water SCHEMBL27886802 | 0.98 | ADORA2A (0.97) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1074972 | 0.90 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.89 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4551803 | 0.89 | ADORA2A (0.91) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| Methylglyoxal SCHEMBL6013418 | 0.87 | ADORA2A (0.76) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23228230 | 0.87 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1741560 | 0.87 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21469779 | 0.87 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL28228476 | 0.87 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114574454-B | Short-chain dehydrogenase, mutant and application thereof | 沈阳药科大学 | 2023-11-17 | — | — | CN | claimed |
| CN-108503643-A | The preparation method of protease inhibitors | 泉州易初生物医药科技有限公司 | 2018-09-07 | — | — | CN | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| EP-1678175-B1 | MEDICAL USE OF ZWITTERIONIC COMPOUNDS BEING CFTR CHANNEL MODULATORS | UNIV JOSEPH FOURIER (FR) | 2008-02-13 | — | — | EP | claimed |
| US-20060258612-A1 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-16 | — | — | US | claimed |
| EP-1678175-A2 | CFTR CHANNEL MODULATORS | Universite Joseph Fourier (FR) | 2006-07-12 | — | — | EP | claimed |
| WO-2005039589-A2 | CFTR CHANNEL MODULATORS | UNIVERSITE JOSEPH FOURIER (FR) | 2005-05-06 | — | — | WO | claimed |
| WO-2024010977-A1 | BIFACIAL PEPTIDE NUCLEIC ACID PROBES AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-117343101-A | Method for preparing antiviral nucleotide analogues | 吉利德科学公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-114574454-B | Short-chain dehydrogenase, mutant and application thereof | 沈阳药科大学 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023186065-A1 | A CYCLIN-DEPENDENT KINASE INHIBITOR | Taizhou Eoc Pharma Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| CN-107266498-B | Method for preparing antiviral nucleotide analogues | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116355017-A | Novel nucleoside reverse transcriptase inhibitors for antiviral use | 深圳市塔吉瑞生物医药有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-7772198-B2 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| EP-1678175-B1 | MEDICAL USE OF ZWITTERIONIC COMPOUNDS BEING CFTR CHANNEL MODULATORS | UNIV JOSEPH FOURIER (FR) | 2008-02-13 | — | — | EP | disclosed |
| US-20060258612-A1 | CFTR channel modulators | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1678175-A2 | CFTR CHANNEL MODULATORS | Universite Joseph Fourier (FR) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005039589-A2 | CFTR CHANNEL MODULATORS | UNIVERSITE JOSEPH FOURIER (FR) | 2005-05-06 | — | — | WO | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258612-A1 | CFTR channel modulators | CFTR, SCNN1B, SCNN1A | ADORA2A 606/4885ADORA1 260/4885ADORA2B 530/4885 |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ADORA2A 1048/4885ADORA1 2085/4885ADORA2B 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.